By Nermeen Nabil Khear 
The scope of pharma’s traditional research efforts is already immense and the industry has been battling stubborn R&D productivity rates for decades. An August analysis in Nature Reviews Drug Discovery estimated that global biopharmaceutical companies collectively poured $276 billion into R&D across more than 4,000 firms in 2021 alone. “If you look at potential value in drug discovery and development, there’s a lot of waste and inefficiency. The failure rate is enormous, especially in clinical stages, and costs are skyrocketing,” Gill said. “There’s a huge opportunity if we apply AI and computational technologies in a robust way.”
With the backing of Big Pharma firms like Merck KGaA (Darmstadt, Germany), AstraZeneca, Pfizer, and Teva, along with cloud giant AWS and support from investors AMITI, Israel Biotech Fund, BioMed X Institute and the Israel Innovation Authority, AION Labs spearheads a systematic transformation of drug discovery and development—one startup at a time. “We pitched it to various pharma companies, along with BioMed X and Israel Biotech Fund,” notes Gill.
Insights from Mati Gill, CEO of AION Labs
“It’s definitely early. Even outside of AI, pharma is one of the last industries to embrace new AI technologies or digital based business-model disruptions.”
A Quick Stat
According to Deloitte’s 2024 Global Life Sciences Sector Outlook, only about 16% of drug discovery efforts were using AI, though triple-digit growth is projected over the next few years.
On the innovator’s dilemma:
“Very few industries actually disrupt themselves. Think about Kodak—they didn’t disrupt photography. Apple did, basically.”
Growing biotech ecosystem:
“It’s growing, for sure. We’re seeing more funds dedicating capital to biotech, more multinationals setting up some R&D presence—like GSK’s AI/ML R&D group in Tel Aviv. Historically in Israel, people with AI skills went into cybersecurity, e-commerce, fintech or ad tech. Now they see bio as an exciting frontier.”
Israeli mindset:
“When you tell Israelis something’s not possible, people here tend to push through anyway.”
The AI talent gap:
“The most AI-savvy entrepreneurs… if they come from an AI background, they’re never going to work for corporate pharma for a lengthy period. It’s a different cultural mindset.”
Different approaches to incorporating emerging tech:
“Among pharma companies, there tend to be two or three different philosophies. One is the hands-off approach: ‘Okay, if you build it, I’ll come. Build a company, prove that it works, and then I’ll buy from it.’ Another is the opposite extreme: ‘I don’t want to partner externally; I just want to build everything in-house.’ On the other hand, [other leading pharmas] take a more hybrid approach. They’re building robust internal capabilities but also recognize that the most cutting-edge AI experts—especially in scientific breakthroughs—won’t necessarily join a corporate pharma R&D – so they need to invest in partnership capabilities.”
A COVID-era coalition
AION Labs partnership itself was born in the middle of the COVID-19 pandemic—formed largely over video calls. “Honestly, it came together faster than it would have without COVID—we spent hundreds of hours on Zoom ironing out structure, governance, and scope,” Gill said.
In addition to the founding partners, the consortium also brought on BioMed X (a German venture studio pioneer) to help shape the model, along with Amiti Ventures as a second VC last year.
The venture studio’s strategy reflects Israel’s unique approach to technological innovation. The old adage about the gold rush and selling picks and shovels illustrates AION Labs’ strategy. Given Israel’s limited domestic market and a tradition of tending to focus on specific technologies over end-to-end systems, the venture studio aims to develop the computational tools and AI platforms that will power the next generation of drug discovery rather than competing directly in traditional pharmaceutical development. “Israel is only about 10 million people, so we can’t rely on having a huge domestic market,” Gill explains. “Instead, we look at where we can add unique value—like Mobileye did in auto-tech. They didn’t build entire cars; they made the enabling vision and AI systems that everyone else started using and implementing in their cars.” Intel eventually acquired Mobileye in 2017 for $15.3 billion.
“We want to replicate that Mobileye approach in biotech. Our startups focus on multi-product platforms or critical enabling and specialized capabilities—like advanced AI algorithms for antibody optimization or epiproteomics—rather than just focusing on specific molecules. It’s more efficient for a small country to become a global hub of breakthrough technologies than to try to do everything ourselves.”
Israel’s burgeoning biotech scene
Gill notes that more Israeli — and international — entrepreneurs are resonating with this specialized, technology-first approach to pharmaceutical innovation. “Now they see that biotech is the next frontier, especially where AI intersects biology. There’s a massive global need, and Israel is well-positioned to supply key innovations without having to build an entire pharma infrastructure.”
Spotlight on PromiseBio, an AION Labs startup that recently emerged from stealth
From left to right: Ronel Veksler, MD, PhD (CEO); Yifat Merbl, PhD (Scientific Co-founder & Associate Professor, Weizmann Institute of Science); and Assaf Kacen, PhD (CTO) [PromiseBio]
Founded
Began stealth operations in early 2024, emerging publicly in December 2024 to introduce its epiproteomics-driven AI platform.
Seed funding
Raised $8.3 million with backing from Awz Ventures and AstraZeneca, Pfizer, and the Israel Innovation Authority (through AION Labs’ seeding track).
Core technology
Builds on years of research at the Weizmann Institute, focusing on protein modifications (PTMs). By analyzing these epiproteomic changes—an approach known to be critical in immune response—PromiseBio aims to address the significant number of patients (as many as 60-70%) who do not experience adequate remission from existing therapies.
Reducing trial-and-error
Recently featured as one of TechCrunch’s 51 most disruptive startups of 2024, PromiseBio’s platform seeks to refine treatment decisions and accelerate drug discovery by providing data-driven tools for selecting the right biologic therapies. This approach is intended to lower healthcare costs and improve patient care by cutting back on prolonged, ineffective treatments.
Israel’s ecosystem also offers other advantages. The country has “all the ingredients that should have led to a robust economic growth engine in biotech,” Gill explains. For instance, it possesses “a strong healthcare system, digitized data, excellent scientific research, top universities, and a lot of government support.” He also points to the country’s culture of rapid innovation and resilience: “We’re a small nation used to solving challenges under pressure—that mindset naturally carries over into biotech.” Gill adds that the Israel Innovation Authority has launched programs specifically aimed at “bio-convergence,” bringing together biology and AI. “They’re co-funding startups and providing non-dilutive grants,” he notes, “which helps de-risk early-stage ventures.”
The momentum is building: “We’re seeing more dedicated biotech funds, more multinational companies setting up some R&D presence—like GSK, which has an AI/ML R&D group in Tel Aviv,” says Gill. Other non AION Labs partner pharmas with R&D investment, collaborations or operations in Israel include Roche, Sanofi, Takeda, and Novartis. As these global players deepen their footprint, more of Israel’s AI-savvy entrepreneurs are gravitating toward biotech. “Historically, a lot of local talent went into cybersecurity or e-commerce, but now they’re seeing the big opportunity in life sciences.”
AION Labs’ approach
AION Labs’ venture studio approach brings fresh energy to an industry that rarely disrupts itself. By zeroing in on real-world R&D pain points—then pairing entrepreneurial scientists with pharma insiders, deep tech expertise, and tangible funding—this coalition aims to break pharma’s slow adoption cycle. Each new startup, whether emerging through the “building” track or the “seeding” track, is guided by milestone-based progress and de-risked by proactive involvement from pharma and AWS. These players help shape proof-of-concept studies, shorten time to pilot, and ensure solutions align with genuine drug-discovery needs.
AION Labs deliberately steers clear of building a product first and hunting for a use case later. Instead, it zeroes in on challenges that multiple pharma partners have already identified as top priorities—assuring each startup of immediate industry interest. Every team also works with a dedicated ‘pharma champion,’ an internal R&D expert who supplies real data, guides proof-of-concept experiments, and delivers prompt feedback. This structure keeps development efforts tied to pressing, real-world needs instead of drifting into purely theoretical work.
Measuring progress
In practice, AION Labs uses milestones to gauge progress. Once a new startup is formed, AION Labs works with founders to set short-term R&D goals—like demonstrating initial proof-of-concept data or hitting key in silico milestones within a set timeframe. “That structure helps us pivot or double down based on what the early data shows,” explains Gill. This milestone-based approach de-risks the usual unpredictability of pharma R&D, ensuring that resources go toward projects that show genuine promise.
In addition to offering the “building” and “seeding” tracks, AION Labs runs a high-intensity, one-week “boot camp” once a specific R&D challenge is defined. “We bring in top candidates from around the world, give them intense workshops, mentorship, and real pharma feedback,” says Gill. “By the end of that week, they pitch to our Scientific Investment Committee.” The “winning” team (or sometimes a merged team) then receives $1 million in pre-seed funding, facilities, mentoring, pharma R&D expertise and administrative, talent and financial support. This boot camp is deliberately “outside their comfort zone,” ensuring that each finalist group has “the right combination of domain expertise, AI skills, entrepreneurial drive and character of the scientist-founders,” as Gill puts it.
Beyond just funneling out new AI-driven ventures, AION Labs is also fostering a culture shift within pharma by bringing fresh talent, novel tech approaches, and big-industry mentorship onto the same playing field. “That’s no small feat,” says Gill, acknowledging that the pharma sector isn’t known for breakneck transformation. “But if we want breakthroughs, we have to take bolder steps. When you say something’s impossible, people here tend to push through anyway.”
This articles is written by : Nermeen Nabil Khear Abdelmalak
All rights reserved to : USAGOLDMIES . www.usagoldmines.com
You can Enjoy surfing our website categories and read more content in many fields you may like .
Why USAGoldMines ?
USAGoldMines is a comprehensive website offering the latest in financial, crypto, and technical news. With specialized sections for each category, it provides readers with up-to-date market insights, investment trends, and technological advancements, making it a valuable resource for investors and enthusiasts in the fast-paced financial world.